Crossmark

Co-encapsulation of norcantharidin prodrugs and lomitapide in nanoparticles to regulate CCL4 expression by inhibiting Wnt/β-catenin pathway for improved anti-tumor immunotherapy

Crossref DOI link: https://doi.org/10.1186/s12951-025-03425-8

Published Online: 2025-05-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Feng

Gong, Liming

Wang, Ping

Chen, Dong

Cao, Shijie

Yang, Feifei

Tang, Manqing

Meng, Yuanyuan

Wang, Yuming

Miao, Lin

Li, Yunfei

Huang, Wei
Funding

Funding for this research was provided by:

Tianjin University of Traditional Chinese Medicine Startup Funding

Open Projects Fund of Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University (2023CCG13)

Jilin Province Science and Technology Development Plan Item (YDZJ202501ZYTS818)

CAMS Innovation Fund for Medical Sciences (2021-I2M-1-026)
License Information

Text and Data Mining valid from 2025-05-21

Version of Record valid from 2025-05-21
More Information

Article History

Received: 13 November 2024

Accepted: 1 May 2025

First Online: 21 May 2025

Declarations

:

: The experimental protocol concerning animals used in this work was approved by the Animal Ethical Committee at Tianjin University of Traditional Chinese Medicine and adhered to the animal care guidelines of Laboratory Animal Management Committee (Approval TCM-LAEC2023114).

: All authors involved in this study have provided their consent for the publication of the research findings.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below